Product
CD19x22 CAR T Cells
1 clinical trial
1 indication
Indication
Non-Hodgkin lymphomaClinical trial
Phase 1/1b Study of Bispecific CD19 and CD22 Chimeric Antigen Receptor Co-Expressing T Cells (CD19x22 CAR T) in Adolescent and Adult Patients With Relapsed and/or Refractory B-Non-Hodgkin's Lymphoma (B-NHL)Status: Recruiting, Estimated PCD: 2024-12-01